On October 22, 2026, Alpha Tau Medical Ltd. announced a significant partnership with Samsung Medical Center (SMC) in South Korea. The two entities signed a memorandum of understanding (MOU) to explore a potential clinical trial of Alpha Tau's innovative alpha-radiation cancer therapy, Alpha DaRT, specifically targeting pancreatic cancer patients. This development is crucial as pancreatic cancer remains one of the deadliest forms of cancer in Korea, with limited treatment options available.
Alpha Tau Medical Ltd. is an Israeli company focused on developing advanced oncology therapeutics. The company is publicly traded on the Nasdaq under the tickers DRTS and DRTSW. Its primary focus is on the research and potential commercialization of the Alpha DaRT technology, which aims to provide effective treatment for solid tumors. The company has been active in filing reports with the SEC, including recent filings on October 22 and October 19, 2026.
The recent filing highlights the signing of an MOU with SMC, which is ranked fifth globally and first in Korea for oncology services. The press release attached to the filing states, "the signing of an MOU in Seoul, South Korea, with Samsung Medical Center (SMC), regarding a potential clinical trial in pancreatic cancer patients." This partnership could pave the way for Alpha Tau to conduct its first clinical trial in Korea, subject to regulatory and ethics committee approvals.
This collaboration is particularly significant given the alarming statistics surrounding pancreatic cancer in Korea. The disease has seen a rise in its death rate, with only about one in five patients undergoing surgery. In 2023, nearly 9,748 Koreans were diagnosed with pancreatic cancer, and the five-year relative survival rate is the lowest among all cancers in the country, at just 17%. The MOU aims to explore new treatment possibilities for these patients, who often have limited options.
The partnership may influence various stakeholders in the healthcare and medical device industries. Patients suffering from pancreatic cancer could benefit from innovative treatment options, while healthcare providers may see an increase in collaborative research opportunities. Additionally, competitors in the surgical and medical instruments sector may need to monitor Alpha Tau's advancements closely, as the company seeks to establish a foothold in the Asian market.
As for the next steps, the filing does not specify what will happen following the signing of the MOU. However, the success of this initiative will depend on obtaining the necessary regulatory approvals to commence the clinical trial.